CA2963276A1 - Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes - Google Patents

Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes Download PDF

Info

Publication number
CA2963276A1
CA2963276A1 CA2963276A CA2963276A CA2963276A1 CA 2963276 A1 CA2963276 A1 CA 2963276A1 CA 2963276 A CA2963276 A CA 2963276A CA 2963276 A CA2963276 A CA 2963276A CA 2963276 A1 CA2963276 A1 CA 2963276A1
Authority
CA
Canada
Prior art keywords
compound
diabetes
alkyl
alkenyl
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2963276A
Other languages
English (en)
French (fr)
Inventor
Lyne Gagnon
Brigitte Grouix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liminal R&D Biosciences Inc
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of CA2963276A1 publication Critical patent/CA2963276A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2963276A 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes Abandoned CA2963276A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062526P 2014-10-10 2014-10-10
US62/062,526 2014-10-10
PCT/CA2015/000531 WO2016054726A1 (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Publications (1)

Publication Number Publication Date
CA2963276A1 true CA2963276A1 (en) 2016-04-14

Family

ID=55652427

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2963276A Abandoned CA2963276A1 (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Country Status (21)

Country Link
US (1) US10105331B2 (enExample)
EP (1) EP3203998B1 (enExample)
JP (1) JP6676629B2 (enExample)
KR (1) KR20170066614A (enExample)
CN (1) CN106999458B (enExample)
AR (1) AR102248A1 (enExample)
AU (1) AU2015330643B2 (enExample)
BR (1) BR112017007420A2 (enExample)
CA (1) CA2963276A1 (enExample)
DK (1) DK3203998T3 (enExample)
ES (1) ES2875336T3 (enExample)
IL (1) IL251392B (enExample)
MX (1) MX376872B (enExample)
PH (1) PH12017500662B1 (enExample)
PL (1) PL3203998T3 (enExample)
PT (1) PT3203998T (enExample)
RU (1) RU2723486C2 (enExample)
SG (1) SG11201702812PA (enExample)
TW (1) TWI699201B (enExample)
UY (1) UY36354A (enExample)
WO (1) WO2016054726A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
US10391073B2 (en) * 2014-11-12 2019-08-27 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CA3112073A1 (en) 2018-10-11 2020-04-16 Basf As Aromatic compounds and pharmaceutical uses thereof
US20240043372A1 (en) * 2020-10-06 2024-02-08 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
RU2005128501A (ru) * 2003-02-13 2006-04-27 Веллстат Терапьютикс Корпорейшн (Us) Соединение для лечения метаболических расстройств
CA2580370A1 (en) * 2004-09-15 2006-03-23 Gokhan S. Hotamisligil Reducing er stress in the treatment of obesity and diabetes
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
JP2012072136A (ja) * 2010-09-03 2012-04-12 Erina Co Inc 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び／又は治療用医薬製剤、機能性食品及び健康食品
CA2816094A1 (en) * 2010-10-27 2012-07-26 Prometic Biosciences Inc. Compounds and pharmaceutical compositions for uses in diabetes
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Also Published As

Publication number Publication date
RU2017116106A3 (enExample) 2019-02-13
WO2016054726A1 (en) 2016-04-14
EP3203998A4 (en) 2018-06-20
CN106999458B (zh) 2021-04-13
EP3203998B1 (en) 2021-03-10
SG11201702812PA (en) 2017-05-30
ES2875336T3 (es) 2021-11-10
KR20170066614A (ko) 2017-06-14
US10105331B2 (en) 2018-10-23
IL251392A0 (en) 2017-05-29
AR102248A1 (es) 2017-02-15
EP3203998A1 (en) 2017-08-16
MX376872B (es) 2025-03-07
RU2017116106A (ru) 2018-11-12
TW201618763A (zh) 2016-06-01
PL3203998T3 (pl) 2021-09-27
MX2017004738A (es) 2017-08-10
AU2015330643A1 (en) 2017-05-04
UY36354A (es) 2016-06-01
PT3203998T (pt) 2021-06-07
PH12017500662B1 (en) 2022-08-19
RU2723486C2 (ru) 2020-06-11
IL251392B (en) 2020-11-30
CN106999458A (zh) 2017-08-01
JP6676629B2 (ja) 2020-04-08
PH12017500662A1 (en) 2017-10-02
AU2015330643B2 (en) 2020-05-14
TWI699201B (zh) 2020-07-21
US20170209399A1 (en) 2017-07-27
JP2017530182A (ja) 2017-10-12
BR112017007420A2 (pt) 2018-01-16
DK3203998T3 (da) 2021-05-31

Similar Documents

Publication Publication Date Title
AU2011356584B2 (en) Compounds and pharmaceutical compositions for uses in diabetes
TW201500043A (zh) 藥學組成物
EP3203998B1 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
US20220409598A1 (en) Method of controlling blood sugar level and treatment of diabetes and related conditions
WO2012090225A2 (en) Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
JP2010522762A (ja) 糖尿病の治療のための方法及びプロブコール誘導体の組成物
JP6360826B2 (ja) 肝機能改善法
HK1236421B (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
CA2598491A1 (en) Diastereoisomers of 4-hydroxyisoleucine and uses thereof
Panina The DPP‐4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond
WO2011002011A1 (ja) Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
Prabavathy et al. Linagliptin-a novel DPP-IV inhibitor
HK40078244A (en) Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
AU2016202866A1 (en) Pharmaceutical compositions
HK1165292A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201002

EEER Examination request

Effective date: 20201002

EEER Examination request

Effective date: 20201002

EEER Examination request

Effective date: 20201002

EEER Examination request

Effective date: 20201002

EEER Examination request

Effective date: 20201002

EEER Examination request

Effective date: 20201002

EEER Examination request

Effective date: 20201002

FZDE Discontinued

Effective date: 20240304